All In Biotech

Drug Trial Radar · NCT00851227

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

A Phase 1, Open-Label Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

Last checked: Nov 19, 2026Latest source record: May 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Feb 2009

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function

Conditions

  • Liver Disease
  • Hyponatremia

Interventions

  • conivaptan hydrochlorideDrug

    intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measure PK and protein binding of conivaptanTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.